News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aphton Corporation (APHT) To Expand Licensing And Commercialization Agreements Into Europe For IGN311



2/7/2006 11:22:53 AM

Aphton Corporation (Pink Sheets:APHT) announced today that its wholly-owned subsidiary, Igeneon, signed a letter of intent with Celltrion to amend their existing licensing and commercialization agreements for the clinical product candidate, IGN311, a humanized monoclonal antibody against the Lewis-Y carbohydrate antigen and Igeneon's next-generation antibody, IGN312.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES